Nyxoah S.A.
NASDAQ:NYXHMedical - Instruments & Supplies
+$0.02 today
- Market cap
- $87.89M
- Beta
- 0.89
- P/E (TTM)
- -0.7
- EPS (TTM)
- -$1.99
Volume 0.17M
Average 0.22M
NYXH Other Income / Expenses
Net non-operating gains and losses, such as investment results, currency effects, and one-off items.
Nyxoah S.A.NASDAQ: NYXH
Other Income / Expenses · Q1 FY2026 · quarter ended Mar 2026
Other income / expenses turns positive
Q1 FY2026 other income / expenses was €5.76M, compared with -€1.62M a year earlier. Trailing-twelve-month other income / expenses was €1.25M.
Context
- Other income / expenses amounted to 61.2% of revenue in FY2025, up 8.6 pp from a year earlier.
- Other income / expenses increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly other income / expenses holds near €5.76M or moves back toward the trailing-twelve-month quarterly average of €311.92K.
Sources:Income StatementText generated from reported figures; not investment advice.
Other Income / Expenses history
EUR · from the income statement
- Latest · FY2025
- (6.13M) EUR
- Year-over-year change
- -358.1%
| Period | Period end | Other Income / Expenses | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (6.13M) | -358.1% |
| FY2024 | 2024-12-31 | 2.38M | +434.2% |
| FY2023 | 2023-12-31 | 445K | -81.8% |
| FY2022 | 2022-12-31 | 2.44M | +52.4% |
| FY2021 | 2021-12-31 | 1.6M | — |
Other Income / Expenses vs competitors
How NYXH compares with its peers on the latest reported figures
- Peers report in different currencies, so other income / expenses is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +265.9% is the highest of 10, against a peer median of -16.4%.
- Other income / expenses amounts to 7.6% of revenue for NYXH, versus a peer median of 7.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $7.57M USD | -41.2% | +161.3% | 1225.4% | |
| LTM Mar 2026 | $6.75M USD | +12.2% | +85.7% | — | |
| LTM Mar 2026 | $4.56M USD | +71.8% | +107.2% | 15.8% | |
| LTM Mar 2026 | $4.17M USD | -16.4% | -23.0% | 7.5% | |
| LTM Mar 2026 | $2.62M USD | -12.7% | +46.1% | 7.0% | |
| LTM Mar 2026 | €1.25M EUR | +265.9% | — | 7.6% | |
| LTM Mar 2026 | $335.48K USD | -23.0% | +49.9% | 0.8% | |
| LTM Mar 2026 | -$208K USD | -104.2% | — | 0.2% | |
| LTM Mar 2026 | -$7.83M USD | +20.6% | — | 5.2% | |
| LTM Mar 2026 | -$35.09M USD | -262.9% | — | 30.8% | |
| Peer median (excluding NYXH) | — | -16.4% | +67.8% | 7.2% | |
Competitors are the stored peer set for NYXH. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 852K | 3.08M | 4.35M | 4.52M | 10.02M |
| Cost of Revenue | 303K | 1.15M | 1.66M | 1.55M | 3.69M |
| Gross Profit | 549K | 1.93M | 2.69M | 2.97M | 6.33M |
| Gross Margin | 64.4% | 62.7% | 61.9% | 65.7% | 63.1% |
| Research & Development | 5.95M | 15.86M | 27.66M | 34.33M | 42.82M |
| Selling, General & Admin | 11.11M | 18.86M | 20.65M | 28.46M | 46.44M |
| Operating Expenses | 26.79M | 34.43M | 47.79M | 61.78M | 89.27M |
| Depreciation & Amortization | 1.66M | 1.93M | 2.36M | 764K | 4.48M |
| EBITDA | (22.59M) | (27.89M) | (42.08M) | (53.77M) | (82.9M) |
| EBITDA Margin | -2651.5% | -904.2% | -967.8% | -1189.2% | -827.4% |
| Operating Income | (26.24M) | (32.5M) | (45.1M) | (58.81M) | (82.94M) |
| Operating Margin | -3080.0% | -1053.8% | -1037.3% | -1300.8% | -827.8% |
| Interest Income | 1K | 372K | 2.57M | 2.5M | 1.83M |
| Interest Expense | 386K | 237K | 1.21M | 1.9M | 1.69M |
| Other Income / Expenses | 1.6M | 2.44M | 445K | 2.38M | (6.13M) |
| Income Before Tax | (24.64M) | (30.06M) | (44.66M) | (56.43M) | (89.08M) |
| Pre-Tax Margin | -2891.9% | -974.6% | -1027.1% | -1248.2% | -889.0% |
| Income Tax Expense | 2.98M | 1.17M | (1.45M) | 2.8M | 1.01M |
| Net Income | (27.62M) | (31.23M) | (43.21M) | (59.24M) | (90.09M) |
| Net Margin | -3241.7% | -1012.5% | -993.8% | -1310.2% | -899.1% |
| EPS (Basic) | (1.16) | (1.21) | (1.55) | (1.81) | (2.37) |
| EPS (Diluted) | (1.16) | (1.21) | (1.55) | (1.81) | (2.37) |
| Weighted Avg Shares | 23.79M | 25.82M | 27.97M | 32.74M | 38.11M |
| Weighted Avg Shares (Diluted) | 23.79M | 25.82M | 27.97M | 32.74M | 38.11M |
Nyxoah S.A.
NASDAQ:NYXH
Intrinsic Alpha fair value
Locked
Current Price
$0.86
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.